Download PDF
Horm Metab Res 2017; 49(10): 760-771
DOI: 10.1055/s-0043-108911
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Correlation Between Circulating Betatrophin and Insulin Resistance in General Population: A Meta-Analysis

Jinling Xu   *
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Yanyan Lin   *
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Hui Zhou
2   Department of General Surgery, Wuhan Third Hospital, Wuhan 430060, China
,
Linshuang Zhao
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Guangda Xiang
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
› Author Affiliations
Further Information

Publication History

received 28 January 2017

accepted 06 April 2017

Publication Date:
20 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Many inconsistent findings are reported on the correlation between circulating betatrophin and insulin resistance in the different population. The aim of this analysis was to explore the correlation between the level of betatrophin and insulin resistance in the general population. The databases of PubMed, EMBASE, and the Cochrane Library (inception to October 26, 2016) were searched without language restrictions for publications that reported studies on associations between betatrophin and insulin resistance in adults. Subgroup analyses were performed to investigate potential sources of heterogeneity. The pooled effect size was calculated using a random-effects model. Twenty-five studies were included in this meta-analysis. Meta-analysis showed that betatrophin was positively and significantly correlated with insulin resistance (r=0.16, 95% CI: 0.08–0.25). When all participants were divided into DM, GDM, and Non-DM groups, this association was also significant in T2DM, GDM, and Non-DM participants (T2DM: r=0.09, 95% CI: 0.01–0.17; I 2=45.1%; GDM: r=0.39, 95% CI: 0.24–0.55; I 2=0.0%; non-DM: r=0.15, 95% CI: 0.04–0.26; I 2=89.3%), and it was obvious that heterogeneity existed in Non-DM group (I 2=89.3%, p<0.001). Subgroup analysis revealed that gender, serum sample and ELISA kits for full-length betatrophin had significant influence on the association between betatrophin and insulin resistance. In conclusion, the level of circulating betatrophin is positively associated with insulin resistance in the general population, especially in T2DM and GDM patients. Gender, serum sample, and ELISA kits for full-length betatrophin may affect this association. More large-scale studies are needed to determine whether improving insulin resistance concomitantly declines betatrophin levels in different diseases.

Key words

betatrophin - insulin resistance - meta-analysis

* Contributed equally to this work, co-first authors


Supplementary Material

    Supplementary Material for this article is available online at http://www.thieme-connect.de/products.
  • Supplementary Material
 

  • References

  • 1 Sah SP, Singh B, Choudhary S, Kumar A. Animal models of insulin resistance: A review. Pharmacol Rep 2016; 68: 1165-1177
    CrossrefPubMedGoogle Scholar
  • 2 Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012; 424: 786-792
    CrossrefPubMedGoogle Scholar
  • 3 Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC, Hobbs HH. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA 2013; 110: 16109-16114
    CrossrefPubMedGoogle Scholar
  • 4 Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA 2012; 109: 19751-19756
    CrossrefPubMedGoogle Scholar
  • 5 Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, Arellano-Campos O, Muñoz-Hernandez LL, Gomez-Munguia L, Ordoñez-Sánchez ML, Reddy PM, Lusis AJ, Matikainen N, Taskinen MR, Riba L, Cantor RM, Sinsheimer JS, Tusie-Luna T, Pajukanta P. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet 2013; 50: 298-308
    CrossrefPubMedGoogle Scholar
  • 6 Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, Stitziel NO, Brody JA, Khetarpal SA, Crosby JR, Fornage M, Isaacs A, Jakobsdottir J, Feitosa MF, Davies G, Huffman JE, Manichaikul A, Davis B, Lohman K, Joon AY, Smith AV, Grove ML, Zanoni P, Redon V, Demissie S, Lawson K, Peters U, Carlson C, Jackson RD, Ryckman KK, Mackey RH, Robinson JG, Siscovick DS, Schreiner PJ, Mychaleckyj JC, Pankow JS, Hofman A, Uitterlinden AG, Harris TB, Taylor KD, Stafford JM, Reynolds LM, Marioni RE, Dehghan A, Franco OH, Patel AP, Lu Y, Hindy G, Gottesman O, Bottinger EP, Melander O, Orho-Melander M, Loos RJ, Duga S, Merlini PA, Farrall M, Goel A, Asselta R, Girelli D, Martinelli N, Shah SH, Kraus WE, Li M, Rader DJ, Reilly MP, McPherson R, Watkins H, Ardissino D, NHLBI GO. Exome Sequencing Project. Zhang Q, Wang J, Tsai MY, Taylor HA, Correa A, Griswold ME, Lange LA, Starr JM, Rudan I, Eiriksdottir G, Launer LJ, Ordovas JM, Levy D, Chen YD, Reiner AP, Hayward C, Polasek O, Deary IJ, Borecki IB, Liu Y, Gudnason V, Wilson JG, van Duijn CM, Kooperberg C, Rich SS, Psaty BM, Rotter JI, O’Donnell CJ, Rice K, Boerwinkle E, Kathiresan S, Cupples LA. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 2014; 94: 223-232
    CrossrefPubMedGoogle Scholar
  • 7 Wang YY, Zhang D, Jiang ZY, Lu XQ, Zheng X, Yu YJ, Wang YG, Dong J. Positive association between betatrophin and diabetic retinopathy risk in type 2 diabetes patients. Horm Metab Res 2016; 48: 169-173
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol 2014; 323407
    PubMedGoogle Scholar
  • 9 Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM, Kiefer FW. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 2014; 57: 1204-1208
    CrossrefPubMedGoogle Scholar
  • 10 Gomez-Ambrosi J, Pascual E, Catalan V, Rodríguez A, Ramírez B, Silva C, Gil MJ, Salvador J, Frühbeck G. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014; 99: E2004-E2009
    CrossrefPubMedGoogle Scholar
  • 11 Gao T, Jin K, Chen P, Jin H, Yang L, Xie X, Yang M, Hu C, Yu X. Circulating betatrophin correlates with triglycerides and postprandial glucose among different glucose tolerance statuses--a case-control study. PLoS One 2015; 10: e0133640
    CrossrefPubMedGoogle Scholar
  • 12 Chen X, Lu P, He W, Zhang J, Liu L, Yang Y, Liu Z, Xie J, Shao S, Du T, Su X, Zhou X, Hu S, Yuan G, Zhang M, Zhang H, Liu L, Wang D, Yu X. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab 2015; 100: E96-E100
    CrossrefPubMedGoogle Scholar
  • 13 Ebert T, Kralisch S, Hoffmann A, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Tönjes A, Fasshauer M. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocrinol Metab 2014; 99: E2510-E2517
    CrossrefPubMedGoogle Scholar
  • 14 Guo K, Lu J, Yu H, Zhao F, Pan P, Zhang L, Chen H, Bao Y, Jia W. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring) 2015; 23: 793-797
    CrossrefPubMedGoogle Scholar
  • 15 Erol O, Ellidag HY, Ayik H, Özel MK, Derbent AU, Yılmaz N. Evaluation of circulating betatrophin levels in gestational diabetes mellitus. Gynecol Endocrinol 2015; 31: 652-656
    CrossrefPubMedGoogle Scholar
  • 16 Xie X, Gao H, Wu S, Zhao Y, Du C, Yuan G, Ning Q, McCormick K, Luo X. Increased cord blood betatrophin levels in the offspring of mothers with gestational diabetes. PLoS One 2016; 11: e0155646
    CrossrefPubMedGoogle Scholar
  • 17 Calan M, Yilmaz O, Kume T, Unal Kocabas G, Yesil Senses P, Senses YM, Temur M. Gursoy Calan 3 O. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine 2016; 53: 271-279
    CrossrefPubMedGoogle Scholar
  • 18 Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Kavalakatt S, Khadir A, Behbehani K, Alarouj M, Bennakhi A, Elkum N. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovas Diabetol 2016; 15: 25
    PubMedGoogle Scholar
  • 19 Lee YH, Lee SG, Lee CJ, Kim SH, Song YM, Yoon MR, Jeon BH, Lee JH, Lee BW, Kang ES, Lee HC, Cha BS. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: Animal and human studies. Sci Rep 2016; 6: 24013
    CrossrefPubMedGoogle Scholar
  • 20 Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB, Behbehani K, Elkum N. Higher plasma betatrophin/ANGPTL8 level in type 2 diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep 2015; 5: 10949
    CrossrefPubMedGoogle Scholar
  • 21 Erbag G, Eroglu M, Turkon H, Sen H, Binnetoglu E, Aylanc N, Asik M. Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome. Cell Mol Bio (Noisy-le-Grand) 2016; 62: 20-24
    PubMedGoogle Scholar
  • 22 Wang L, Song J, Wang C, Lin P, Liang K, Sun Y, He T, Li W, Zhao R, Qin J, Lu Y, Liu J, Liu F, Hou X, Chen L. Circulating levels of betatrophin and irisin are not associated with pancreatic beta-cell function in previously diagnosed type 2 diabetes mellitus patients. J Diabetes Res 2016; 2616539
    PubMedGoogle Scholar
  • 25 Turkon H, Yalcin H, Toprak B, Demirpençe M, Yaşar HY, Colak A. Correlation between bethatrophin and 25(OH)D concentrations in a group of subjects with normal and impaired glucose metabolism. Exp Clin Endocrinol Diabetes 2017; 125: 147-150
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Xie X, Gao T, Yang M, Chen P, Jin H, Yang L, Yu X. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetol Metab Syndr 2015; 7: 26
    CrossrefPubMedGoogle Scholar
  • 23 Yi M, Chen RP, Yang R, Guo XF, Zhang JC, Chen H. Betatrophin acts as a diagnostic biomarker in type 2 diabetes mellitus and is negatively associated with HDL-cholesterol. Int J Endocrinol 2015; 2015: 479157
    PubMedGoogle Scholar
  • 26 Al-Daghri NM, Rahman S, Sabico S, Amer OE, Wani K, Ansari MG, Al-Attas OS, Kumar S, Alokail MS. Circulating betatrophin in healthy control and type 2 diabetic subjects and its association with metabolic parameters. J Diabetes Complications 2016; 30: 1321-1325
    CrossrefPubMedGoogle Scholar
  • 27 Liu D, Qu H, Wang H, Duan Y, Liu F, Feng Z, Deng H. Relationship between serum betatrophin levels and the first-phase of glucose-stimulated insulin secretion. Obes Res Clin Pract 2016; pii: S1871- 403X(16)30075-8.
    PubMed
  • 28 Yilmaz H, Cakmak M, Darcin T, Demir C, Inan O, Ceydilek B, Onaran Y, Bavbek N, Bilgic MA, Akcay A. Elevated plasma levels of betatrophin in women with gestational diabetes mellitus. Exp Clin Endocrinol Diabetes 2015; 123: 376-381
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Huang Y, Fang C, Ma Z, Guo H, Wang R, Hu J. Betatrophin Levels were Increased in Pregnant Women with or without Gestational Diabetes Mellitus and Associated with Beta Cell Function. Rev Bras Ginecol Obstet 2016; 38: 287-292
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Wawrusiewicz-Kurylonek N, Telejko B, Kuzmicki M, Sobota A, Lipinska D, Pliszka J, Raczkowska B, Kuc P, Urban R, Szamatowicz J, Kretowski A, Laudanski P, Gorska M. Increased maternal and cord blood betatrophin in gestational diabetes. PLoS One 2015; 10: e0131171
    CrossrefPubMedGoogle Scholar
  • 31 Sahin Ersoy G, Altun Ensari T, Vatansever D, Emidar V, Cevik O. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol endocrinol 2016; 32: 1-5
    PubMedGoogle Scholar
  • 32 Barja-Fernandez S, Folgueira C, Seoane LM, Casanueva FF, Dieguez C, Castelao C, Agüera Z, Baños R, Botella C, de la Torre R, Fernández-García JC, Fernández-Real JM, Frühbeck G, Gómez-Ambrosi J, Jiménez-Murcia S, Tinahones FJ, Estivill X, Fernández-Aranda F, Nogueiras R. Circulating betatrophin levels are increased in anorexia and decreased in morbidly obese women. J Clin Endocrinol Metab 2015; 100: E1188-E1196
    CrossrefPubMedGoogle Scholar
  • 33 Zhu J, Li C, Dai Y, Fang Z, Zhao D, Zhu H, Wan X, Wang Y, Yu C, Li YM. Serum betatrophin level increased in subjects with nonalcoholic fatty liver disease. Int J Clin Exp Med 2016; 9: 6580-6588
    PubMedGoogle Scholar
  • 34 Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep 2014; 4: 5013
    PubMedGoogle Scholar
  • 35 Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, Wang D, Yang L, Wang J, Mao C, Zhou L, Yuan G. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes care 2014; 37: 2718-2722
    CrossrefPubMedGoogle Scholar
  • 36 Franconi F, Campesi I, Occhioni S, Tonolo G. Sex-gender differences in diabetes vascular complications and treatment. Endocr Metab Immune Disord Drug Targets 2012; 12: 179-196
    CrossrefPubMedGoogle Scholar
  • 37 Fu Z, Abou-Samra AB, Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia 2014; 57: 2232-2234
    CrossrefPubMedGoogle Scholar
  • 38 Li S, Liu D, Li L, Li Y, Li Q, An Z, Sun X, Tian H. Circulating betatrophin in patients with type 2 diabetes: A meta-analysis. J Diabetes Res 2016; 6194750
    PubMedGoogle Scholar
  • 39 Rong Guo X, Li Wang X, Chen Y, Hong Yuan Y, Mei Chen Y, Ding Y, Fang J, Jiao Bian L, Sheng Li D. ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3beta or Akt-FoxO1 pathway in HepG2 cells. Exp Cell Res 2016; 345: 158-167
    CrossrefPubMedGoogle Scholar
  • 40 Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells. Mol Cell Endocrinol 2015; 414: 148-155
    CrossrefPubMedGoogle Scholar
  • 41 Gilbert RE, Thai K, Advani SL, Cummins CL, Kepecs DM, Schroer SA, Woo M, Zhang Y. SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes. Diabetologia 2015; 58: 819-827
    CrossrefPubMedGoogle Scholar
  • 42 Arias-Loste MT, Garcia-Unzueta MT, Llerena S, Iruzubieta P, Puente A, Cabezas J, Alonso C, Cuadrado A, Amado JA, Crespo J, Fábrega E. Plasma betatrophin levels in patients with liver cirrhosis. World J Gastroenterol 2015; 21: 10662-10668
    CrossrefPubMedGoogle Scholar